Key highlights from CVS Health Corporation (CVS) Q2 2023 Earnings Concall Management Update: [00:14:22] CVS said its restructuring efforts are expected to
CVS Health Corporation Q2 2023 Earnings Conference Call Insights
Categories
Biotechnology
CVS Health Q2 2023 earnings drop despite higher revenues
Healthcare conglomerate CVS Health Corporation (NYSE: CVS) announced second-quarter 2023 results, reporting lower earnings despite an increase in revenues. June quarter adjusted
Ocean Biomedical shares details of its successful lung cancer program on World Lung Cancer Day
Biopharmaceutical company Ocean Biomedical, Inc. (NASDAQ: OCEA) provided details of its multi-pronged lung cancer program built on novel immunotherapy discoveries by the
BMY Earnings: A snapshot of Bristol-Myers Squibb’s Q2 2023 results
Biotechnology company Bristol Myers Squibb (NYSE: BMY) on Thursday said its second-quarter adjusted earnings decreased year-over-year, hurt by a fall in revenues.
AbbVie (ABBV) Q2 2023 Earnings: Key financials and quarterly highlights
AbbVie (NYSE: ABBV) reported second quarter 2023 earnings results today. Worldwide net revenues were $13.8 billion, down 4.9% on a reported basis,
BIIB Earnings: A snapshot of Biogen’s Q2 2023 financial results
Biotechnology firm Biogen Inc. (NASDAQ: BIIB) reported lower earnings, on an adjusted basis, and revenues for the second quarter of 2023. Total
Infographic: Thermo Fisher Scientific (TMO) Q2 2023 Earnings Results
Thermo Fisher Scientific Inc. (NYSE: TMO) reported second quarter 2023 earnings results today. Revenue declined 3% to $10.69 billion compared to the
Infographic: Highlights of UnitedHealth Group’s (UNH) Q2 2023 earnings
Diversified healthcare company UnitedHealth Group (NYSE: UNH) reported higher earnings and revenues for the second quarter of 2023. The company also raised
Ocean Biomedical focuses its malaria program to address chronic malaria crisis in sub-Saharan Africa
Biopharma company Ocean Biomedical, Inc. (NASDAQ: OCEA) on Tuesday said it is focusing its multi-pronged malaria program to address the chronic malaria
Apogee Therapeutics set to go public. Here’s what you need to know
The US IPO market has remained mostly sluggish so far this year, continuing the weakness experienced in 2022. Meanwhile, there is speculation
Ocean Biomedical (OCEA) joins the Russell 2000 Index
Ocean Biomedical, Inc. (NASDAQ: OCEA) on Tuesday said it has been included in the Russell 2000 Index and the broad-market Russell 3000
Ocean Biomedical granted US patent for bispecific cancer immunotherapy treatment
Biotechnology company Ocean Biomedical, Inc. (NASDAQ: OCEA) on Monday said its scientific co-founder Dr. Jack Elias has been granted a new, broad
Ocean Biomedical extends patent rights for idiopathic pulmonary fibrosis discovery to Europe
Biopharma company Ocean Biomedical, Inc. (NASDAQ: OCEA) on Friday revealed that its scientific co-founder Dr. Jack Elias has received notice from the
Walgreens Boots Alliance (WBA) set to report Q3 results. What’s in the cards
Walgreens Boots Alliance, Inc. (NASDAQ: WBA), a leading retailer and wholesaler of health and wellness products, is scheduled to report third-quarter earnings
Avid Bioservices Inc. (CDMO) Q4 2023 Earnings Call Transcript
Avid Bioservices Inc. (NASDAQ: CDMO) Q4 2023 earnings call dated Jun. 21, 2023 Corporate Participants: Tim Brons -- Investor Relations Nicholas Green -- President and Chief
Fundamental Research Corp. raises Ocean Biomedical’s price target to $17.63 per share
Ocean Biomedical, Inc. (NASDAQ: OCEA) on Wednesday said that Fundamental Research Corp. increased the price target of the company’s stock to $17.63
Earnings Summary: A snapshot of Catalent’s Q3 2023 results
Catalent, Inc. (NYSE: CTLT), a provider of delivery technologies and development solutions to the pharmaceutical industry, has reported earnings for the third
Ocean Biomedical’s scientific co-founder Dr. Jonathan Kurtis gets new patent for malaria vaccine
Ocean Biomedical, Inc. (NASDAQ: OCEA), a biopharmaceutical company focused on clinical programs in oncology, fibrosis, and infectious disease, Thursday said its scientific
Taglich Brothers initiates coverage of Ocean Biomedical, with price target of $20
Biopharma company Ocean Biomedical, Inc. (NASDAQ: OCEA) on Thursday revealed that Taglich Brothers initiated coverage on the company with a share price
Ocean Biomedical (OCEA) set to join the Russell 2000 Index
Biopharmaceutical company Ocean Biomedical (NASDAQ: OCEA) on Thursday said it is expected to be added to the Russell 2000 Index, effective after
Ocean Biomedical (OCEA) announces patent award for novel cancer immunotherapy treatment
Biopharma company Ocean Biomedical (NASDAQ: OCEA) on Tuesday said its scientific co-founder Dr. Jack Elias has been issued a broad patent for